GRAIL, Inc.
GRAIL Reports Third Quarter 2026 Financial Results
FDA Advisory Committee Voted in Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test Q3 Galleri®Test Volume Increased ~24% to More…
Company newsroom
NASDAQ:GRAL
1 releases
FDA Advisory Committee Voted in Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test Q3 Galleri®Test Volume Increased ~24% to More…